Mahagna 2016.

Methods	Randomised, double‐blind, placebo‐controlled, parallel‐group 2 medical centres in Israel Duration of screening and washout not reported, 6 weeks parallel group phase LOCF imputation for withdrawals No NSAID or coxib for 2 weeks before enrolment No stated minimum pain intensity
Participants	Etoricoxib: N = 32; 100% female; race not reported; mean age 49.8 (SD 13.2) years; pain baseline 6.4 ± 1.7 on BPI; years since diagnosis 3.5 (SD 6.2) years Placebo: N = 32; 100% female; race not reported; mean age 51.0 (SD 9.7) years; pain baseline 6.4 ± 1.8 on BPI; years since diagnosis 5.2 (SD 6.6) years Inclusion criteria: ACR 1990 criteria Exclusion criteria: confirmed pregnancy or breast feeding, with active or previous coronary artery disease, congestive heart failure, coexisting neoplastic conditions (not including basal cell carcinoma), coexisting rheumatic conditions, active or previous gastrointestinal bleeding, renal failure, comorbid conditions causing significant disability and those with uncontrolled hypertension
Interventions	Etoricoxib 90 mg fixed dose Placebo
Outcomes	Pain: Brief Pain inventory NRS 0‐10; 30% and 50% and more pain relief rates reported PGIC much or very much improved: not assessed Fatigue: FIQ VAS 0‐10 subscale scores not reported Sleep problems: FIQ VAS 0‐10 subscale scores not reported Adverse events (AEs): "Assessment of adverse effects was conducted by actively addressing this issue with each patient at each encounter." Health‐related quality of life: FIQ total score 0‐100 Psychological distress: SF‐36 mental health summary score (50‐0)
Notes	Oxford Quality Score R = 1 DB = 1 W = 1 Total = 3/5 No conflicts of interest reported Funding source ‐ MSD
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details reported
Allocation concealment (selection bias)	Unclear risk	No details reported
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details reported
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participant‐reported outcomes; participants were adequately blinded to intervention. Blinding of outcome assessors of safety not adequately described
Incomplete outcome data (attrition bias) All outcomes	High risk	Most secondary outcomes not reported
Selective reporting (reporting bias)	Low risk	Pain baseline scores reported
Group similarity at baseline	Low risk	Similar at baseline
Sample size bias	High risk	Fewer than 50 participants per treatment arm